Current and Emerging Small-Molecule Targeted Agents in Key Oncology Indications | Physician & Payer Forum | Brazil and Mexico | 2015
Securing Market Share and Payer Acceptance in Increasingly Crowded and Segmented Markets in Brazil and Mexico
Small molecule therapies offer specific targeting of the aberrant cellular signaling that underlies a certain cancer, without the nonspecific and often less tolerable effects of chemotherapy treatments. However, uptake of targeted therapies in Mexico and Brazil is highly dependent on incorporation into publically funded formularies which vary widely between countries, in terms of drugs and indications covered. As multiple marketed and late-stage emerging agents seek to optimize the market access opportunities offered, this report assesses how the rising cost of targeted medicine is balanced with clinical need in non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).
